Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2011
04/21/2011US20110092598 Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
04/21/2011US20110092597 Method for treating herpes virus infection
04/21/2011US20110092596 Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
04/21/2011US20110092595 Compositions and Methods for Treating Lung Cancer
04/21/2011US20110092594 Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
04/21/2011US20110092593 Water-Soluble Colonoscopy Lubricant
04/21/2011US20110092592 Diagnosis and treatment of hepatic disorder
04/21/2011US20110092591 Phenyl-prenyl derivatives, of marine and synthetic origin, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
04/21/2011US20110092590 Nitric oxide donating prostamides
04/21/2011US20110092589 Treatment of Inflammatory Conditions and Diseases with Metal-Thiols
04/21/2011US20110092588 Lactone formulations and method of use
04/21/2011US20110092587 Branched-chain amino acid composition for improving skeletal muscle protein metabolism
04/21/2011US20110092586 Apoptosis inductor extracted from potato, potato foodstuff containing the inductor, and processed product thereof
04/21/2011US20110092585 Immunomodulatory pharmaceutical composition and a process for preparation thereof
04/21/2011US20110092584 Therapeutic use of quinonoid derivatives of cannabinoids
04/21/2011US20110092583 Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery
04/21/2011US20110092582 New Terpenes And Macrocycles
04/21/2011US20110092581 Docetaxel Formulations with Lipoic Acid
04/21/2011US20110092580 Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
04/21/2011US20110092579 Solubilized formulation of docetaxel
04/21/2011US20110092578 Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species
04/21/2011US20110092577 Inositol Pyrophosphates Determine Exocytotic Capacity
04/21/2011US20110092576 Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
04/21/2011US20110092575 Sirna of human osteopontin
04/21/2011US20110092574 mRNA Cap Analogs
04/21/2011US20110092573 Modification of myd88 splicing using modified oligonucleotides
04/21/2011US20110092572 Modulation of growth hormone receptor expression and insulin-like growth factor expression
04/21/2011US20110092571 Compositions and methods for sirna inhibition of icam-1
04/21/2011US20110092570 Oligomeric compounds comprising tricyclic nucelosides and methods for their use
04/21/2011US20110092569 Administration of Exogenous mi/siRNA
04/21/2011US20110092568 Modulation of mlck-l expression and uses thereof
04/21/2011US20110092567 Cannabinoid 2 (Cb2) Receptor Gene Promoter and Unique RNA Transcripts in B Cells and Methods of Use
04/21/2011US20110092566 Treatment of cancer with aldose reductase inhibitors
04/21/2011US20110092565 Method of treating neurodegenerative disease
04/21/2011US20110092564 Cyclic amino acids for the treatment of pain
04/21/2011US20110092563 Statin and omega-3 fatty acids for lipid therapy
04/21/2011US20110092562 Method for wetting a powder containing benzoyl peroxide
04/21/2011US20110092561 Benzoisoindole derivatives for the treatment of pain
04/21/2011US20110092560 Topical composition for controlling ectoparasites in dogs and cats
04/21/2011US20110092559 Pyrrole and pyrazole daao inhibitors
04/21/2011US20110092557 Neuraminidase Inhibitors And Compositions And Methods Related Thereto
04/21/2011US20110092555 Thiazolidinedione compound
04/21/2011US20110092554 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
04/21/2011US20110092553 Substituted Azole Derivatives, Compositions, and Methods of Use
04/21/2011US20110092552 Treatment and Prevention of Major Adverse Cardiovascular Events or Major Coronary Events by Administering Omega-3 Fatty Acids
04/21/2011US20110092551 Dual-acting imidazole antihypertensive agents
04/21/2011US20110092549 Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone
04/21/2011US20110092548 Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical
04/21/2011US20110092547 Chemical compounds 979
04/21/2011US20110092546 Substituted benzimidazoles for neurofibromatosis
04/21/2011US20110092545 Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding
04/21/2011US20110092543 Wound And Mucosa Antiseptic Based on Bispyridiniumalkanes
04/21/2011US20110092542 Methods for treating spinal cord injury with a compound that inhibits a ncca-atp channel
04/21/2011US20110092541 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
04/21/2011US20110092540 Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands
04/21/2011US20110092539 Indane derivatives as ampa receptor modulators
04/21/2011US20110092538 Compounds and methods for kinase modulation, and indications therefor
04/21/2011US20110092537 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System
04/21/2011US20110092536 Novel anti-infectious derivatives, method for the production thereof, pharmaceutical compositions containing same and uses of said derivatives in treatment
04/21/2011US20110092535 Novel Epilepsy Treatment
04/21/2011US20110092534 Ammosamides as Anticancer Agents
04/21/2011US20110092533 Compounds for binding to er alpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof
04/21/2011US20110092532 Apomorphine pharmaceutical dosage security system
04/21/2011US20110092531 Novel Spiropiperidine Compounds
04/21/2011US20110092530 Cyclopamine tartrate salt and uses thereof
04/21/2011US20110092529 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists
04/21/2011US20110092528 Piperidinyl compounds that selectively bind integrins
04/21/2011US20110092527 4 (Pyrrolopyridinyl)pyrimidin-2-ylamine derivatives
04/21/2011US20110092526 Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826
04/21/2011US20110092525 Gabaa receptor modulators
04/21/2011US20110092524 Agent for Enhancing Corneal Epithelial Barrier Function
04/21/2011US20110092523 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
04/21/2011US20110092522 Wound and Skin Care Procuts
04/21/2011US20110092521 Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases
04/21/2011US20110092520 Process for producing bicycloaniline derivatives
04/21/2011US20110092519 5,7-disubstituted thiazolo[4,5-d]pyrimidines as chemokine inhibitors
04/21/2011US20110092517 Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases
04/21/2011US20110092516 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases
04/21/2011US20110092515 Melt granulation process
04/21/2011US20110092514 Compounds with anti-cancer activity
04/21/2011US20110092513 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
04/21/2011US20110092512 New hsl inhibitors useful in the treatment of diabetes
04/21/2011US20110092511 Inhibitors of akt activity
04/21/2011US20110092510 Dpp-iv inhibitors for use in the treatment of nafld
04/21/2011US20110092509 Pharmaceutical Composition for Prevention or Treatment of Disease Associated with Tear Reduction
04/21/2011US20110092508 Biomarkers of tumor pharmacodynamic response
04/21/2011US20110092507 Process for preparing R-(+)-3-morpholino-4-(3- tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
04/21/2011US20110092506 Trisubstituted amine compound
04/21/2011US20110092505 Organic compounds
04/21/2011US20110092504 Inhibitors of pi3 kinase
04/21/2011US20110092503 Quinoline derivatives as axl kinase inhibitors
04/21/2011US20110092502 Diaminothiazoles useful as axl inhibitors
04/21/2011US20110092501 Novel inhibitors
04/21/2011US20110092500 Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment
04/21/2011US20110092499 N-containing heterocyclic compounds
04/21/2011US20110092498 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors
04/21/2011US20110092497 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
04/21/2011US20110092496 Thiophene compounds and thrombopoietin receptor activators
04/21/2011US20110092495 Compounds for the treatment of multi-drug resistant bacterial infections
04/21/2011US20110092494 Tricyclic Tetrahydroquinoline Antibacterial Agents